Samuel Costello
Adelaide Medical School
Faculty of Health and Medical Sciences
Dr Samuel Costello - MBBS FRACP PhD - TITLEHOLDER.
Gastroenterologist
Dr Costello graduated from medical school at the University of Adelaide in 2004 and then completed basic physician training at the Royal Adelaide Hospital followed by Gastroenterology training at The Queen Elizabeth Hospital and Repatriation general hospital. He undertook a clinical fellowship in inflammatory bowel disease at St Mark’s hospital in London in 2016.
Dr Costello is a staff specialist at The Queen Elizabeth Hospital and a consultant with the inflammatory bowel disease service. He is the co-lead of IBD research at The Queen Elizabeth Hospital. Dr Costello established and continues to manage the South Australian faecal microbiota transplantation (FMT) service for the treatment of Clostridium difficile infection and has advised other groups in Australia and internationally about developing similar services.
Dr Costello is passionate about medical research. He completed a PhD at the University of Adelaide where the focus of his research was FMT as a treatment for ulcerative colitis. He has published multiple papers in peer-reviewed international journals and has been an invited speaker at national and international conferences on the topics of FMT and microbial therapeutics.
Dr Costello co-founded microbial therapeutics company BiomeBank in 2018, that supplies donor derived FMT product to Australian hospitals and is developing second generation defined microbial therapies. Dr Costello is Chief Medical Officer and a Director of BiomeBank.
Sam enjoys teaching both medical students as well as doctors in training and is a clinical lecturer at the University of Adelaide.
-
Appointments
Date Position Institution name 2020 - ongoing Chief Medial Officer Biomebank 2019 - 2020 CEO BiomeBank 2015 - ongoing Clnical Lecturer University of Adelaide 2013 - ongoing Gastroenterologist The Queen Elizabeth Hospital -
Education
Date Institution name Country Title University of Adelaide Australia MBBS University of Adelaide Australia PhD -
Postgraduate Training
Date Title Institution Country Gastroenterology Royal Australasian College of Physicians Australia
-
Journals
Year Citation 2024 Schubert, J. P., Ingram, P. R., Warner, M. S., Rayner, C. K., Roberts-Thomson, I. C., Costello, S. P., & Bryant, R. V. (2024). Author reply to Hettiarachchi et al. (re Helicobacter pylori resistance in Australia…). Internal Medicine Journal, 54(2), 356-357.
2023 Bosnjak, M., Karpe, A. V., Van, T. T. H., Kotsanas, D., Jenkin, G. A., Costello, S. P., . . . Lyras, D. (2023). Multi-omics analysis of hospital-acquired diarrhoeal patients reveals biomarkers of enterococcal proliferation and Clostridioides difficile infection. Nature Communications, 14(1), 7737-1-7737-16.
Scopus3 Europe PMC32023 Li, A., Bowen, J. M., Ball, I. A., Wilson, S., Yong, A., Yeung, D. T., . . . Wardill, H. R. (2023). Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study. Biomedicines, 11(12), 1-9.
Scopus12023 Bogatic, D., Bryant, R. V., Lynch, K. D., & Costello, S. P. (2023). Cover Image. Alimentary Pharmacology & Therapeutics, 57(1).
2023 Raja, S. S., Bryant, R. V., Costello, S. P., Barnett, M., Schubert, J., & Rayner, C. K. (2023). Systematic review of therapies for refractory ulcerative proctitis. Journal of Gastroenterology and Hepatology (Australia), 38(4), 496-509.
Scopus4 WoS2 Europe PMC12023 Castle, J. W., Butzbach, D. M., Walker, G. S., Lenehan, C. E., Reith, F., Costello, S. P., & Kirkbride, K. P. (2023). Microbial degradation products of lurasidone and their significance in postmortem toxicology. Drug Testing and Analysis, 15(5), 551-565.
2023 Tucker, E. C., Haylock-Jacobs, S., Rapaic, M., Dann, L. M., Bryant, R. V., & Costello, S. P. (2023). Stool donor screening within a Therapeutic Goods Administration compliant donor screening program for fecal microbiota transplantation. JGH Open, 7(3), 172-177.
Scopus4 WoS2 Europe PMC22023 Lopetuso, L. R., Deleu, S., Godny, L., Petito, V., Puca, P., Facciotti, F., . . . Scaldaferri, F. (2023). The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease. Gut, 72(9), 1642-1650.
Scopus37 WoS6 Europe PMC222023 Schubert, J. P., Ingram, P. R., Warner, M. S., Rayner, C. K., Roberts-Thomson, I. C., Costello, S. P., & Bryant, R. V. (2023). Refractory Helicobacter pylori infection in Australia: updated multicentre antimicrobial resistance. Internal Medicine Journal, 53(11), 1972-1978.
Scopus5 Europe PMC12023 Castle, J. W., Butzbach, D. M., Walker, G. S., Lenehan, C. E., Reith, F., Costello, S. P., & Kirkbride, K. P. (2023). In vitro degradation of ziprasidone in human whole blood. Drug Testing and Analysis, 15(2), 220-234.
2022 Bogatic, D., Bryant, R. V., Lynch, K. D., & Costello, S. P. (2022). Microbial manipulation as therapy for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 57(1), 23-36.
Scopus6 Europe PMC42022 Schubert, J. P., Rayner, C. K., Costello, S. P., Roberts-Thomson, I. C., Forster, S. C., & Bryant, R. V. (2022). Helicobacter pylori: Have potential benefits been overlooked?. JGH Open, 6(11), 735-737.
Scopus4 WoS1 Europe PMC22022 Castle, J. W., Butzbach, D. M., Reith, F., Walker, G. S., Lenehan, C. E., Costello, S. P., & Kirkbride, K. P. (2022). Investigations into the stability of 17 psychoactive drugs in a “simulated postmortem blood” model. Drug Testing and Analysis, 14(7), 1200-1222.
Scopus2 WoS22022 Wardill, H. R., Chan, R. J., Chan, A., Keefe, D., Costello, S. P., & Hart, N. H. (2022). Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations.. Support Care Cancer, 30(8), 6369-6373.
Scopus7 WoS6 Europe PMC62022 Schubert, J. P., Woodman, R. J., Mangoni, A. A., Rayner, C. K., Warner, M. S., Roberts-Thomson, I. C., . . . Bryant, R. V. (2022). Geospatial analysis of Helicobacter pylori infection in South Australia: should location influence eradication therapy?. Journal of gastroenterology and hepatology, 37(7), 1263-1274.
Scopus7 WoS4 Europe PMC42022 Day, A. S., Yao, C. K., Costello, S. P., Ruszkiewicz, A., Andrews, J. M., Gibson, P. R., & Bryant, R. V. (2022). Therapeutic Potential of the 4 Strategies to SUlfide-REduction (4-SURE) Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open-Label Feasibility Study. Journal of Nutrition, 152(7), 1690-1701.
Scopus17 WoS8 Europe PMC122022 Gulliver, E. L., Young, R. B., Chonwerawong, M., D'Adamo, G. L., Thomason, T., Widdop, J. T., . . . Forster, S. C. (2022). Review article: the future of microbiome-based therapeutics. Alimentary Pharmacology and Therapeutics, 56(2), 192-208.
Scopus35 WoS7 Europe PMC202022 Soo, W. T., Costello, S. P., & Bryant, R. V. (2022). Dialing Back M for Monoclonal: Successful De-escalation of Dose-Intensified Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 67(1), 8-10.
Scopus22022 Day, A. S., Yao, C. K., Costello, S. P., Andrews, J. M., & Bryant, R. V. (2022). Food-related quality of life in adults with inflammatory bowel disease is associated with restrictive eating behaviour, disease activity and surgery: A prospective multicentre observational study. Journal of Human Nutrition and Dietetics, 35(1), 234-244.
Scopus23 WoS13 Europe PMC122022 Santos-Paulo, S., Costello, S. P., Forster, S. C., Travis, S. P., & Bryant, R. V. (2022). The gut microbiota as a therapeutic target for obesity: A scoping review. Nutrition Research Reviews, 35(2), 207-220.
Scopus19 WoS11 Europe PMC122021 Bryant, R. V., Day, A. S., McGrath, K. C., Telfer, K., Yao, C. K., & Costello, S. P. (2021). Fecal microbiota transplantation augmented by a sulfide-reducing diet for refractory ulcerative colitis: A case report with functional metagenomic analysis. JGH Open, 5(9), 1099-1102.
Scopus10 WoS5 Europe PMC42021 Day, A. S., Yao, C. K., Costello, S. P., Andrews, J. M., & Bryant, R. V. (2021). Food avoidance, restrictive eating behaviour and association with quality of life in adults with inflammatory bowel disease: A systematic scoping review. Appetite, 167, 16 pages.
Scopus38 WoS15 Europe PMC252021 Goodsall, T. M., Noy, R., Nguyen, T. M., Costello, S. P., Jairath, V., & Bryant, R. V. (2021). Systematic review: Patient perceptions of monitoring tools in inflammatory bowel disease. Journal of the Canadian Association of Gastroenterology, 4(2), E31-E41.
Scopus32 Europe PMC172021 Davis, R., Day, A., Barrett, J., Vanlint, A., Andrews, J. M., Costello, S. P., & Bryant, R. V. (2021). Habitual dietary fibre and prebiotic intake is inadequate in patients with inflammatory bowel disease: findings from a multicentre cross-sectional study.. Journal of Human Nutrition and Dietetics, 34(2), 420-428.
Scopus16 WoS12 Europe PMC112021 Schubert, J. P., Warner, M. S., Rayner, C. K., Roberts-Thomson, I., Mangoni, A. A., Costello, S., & Bryant, R. V. (2021). Increasing Helicobacter pylori clarithromycin resistance in Australia over 20 years. Internal Medicine Journal, 52(9), 1554-1560.
Scopus16 WoS6 Europe PMC92021 Schubert, J. P., Gehlert, J., Rayner, C. K., Roberts-Thomson, I. C., Costello, S., Mangoni, A. A., & Bryant, R. V. (2021). Antibiotic Resistance of Helicobacter pylori in Australia and New Zealand: A Systematic Review and Meta-analysis. Journal of gastroenterology and hepatology, 36(6), 1450-1456.
Scopus18 WoS10 Europe PMC132021 Day, A. S., Davis, R., Costello, S. P., Yao, C. K., Andrews, J. M., & Bryant, R. V. (2021). The Adequacy of Habitual Dietary Fiber Intake in Individuals With Inflammatory Bowel Disease: A Systematic Review. Journal of the Academy of Nutrition and Dietetics, 121(4), 688-708.e3.
Scopus21 WoS11 Europe PMC92021 Ianiro, G., Mullish, B. H., Hvas, C. L., Segal, J. P., Kuijper, E. J., Costello, S. P., . . . Cammarota, G. (2021). SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 6(4), 264-266.
Scopus7 WoS5 Europe PMC32021 Deputy, M., Segal, J., Reza, L., Worley, G., Costello, S., Burns, E., . . . Hart, A. (2021). The pouch behaving badly: management of morbidity after ileal pouch–anal anastomosis. Colorectal Disease, 23(5), 1193-1204.
Scopus7 WoS5 Europe PMC12020 Chande, N., Costello, S. P., Limketkai, B. N., Parker, C. E., Nguyen, T. M., MacDonald, J. K., & Feagan, B. G. (2020). Alternative and complementary approaches for the treatment of inflammatory bowel disease: Evidence from cochrane reviews. Inflammatory Bowel Diseases, 26(6), 843-851.
Scopus7 WoS6 Europe PMC62020 Goodsall, T. M., Costello, S. P., & Bryant, R. V. (2020). Histological Healing in Ulcerative Colitis: Near Enough Is Not Good Enough. Journal of Crohn's and Colitis, 14(10), 1341-1342.
Scopus2 WoS1 Europe PMC22020 Aysha, A. -A., Rentsch, C., Prentice, R., Johnson, D., Bryant, R. V., Ward, M. G., . . . Christensen, B. (2020). Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty.. Intern Med J, 50(7), 798-804.
Scopus12 WoS10 Europe PMC112020 Ianiro, G., Mullish, B. H., Kelly, C. R., Kassam, Z., Kuijper, E. J., Ng, S. C., . . . Cammarota, G. (2020). Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic.. Gut, 69(9), 1555-1563.
Scopus125 WoS82 Europe PMC732020 Vanlint, A. S., Kaazan, P., Kwok, M., Bryant, R. V., Ooi, M., Bak, N., & Costello, S. (2020). Lessons from practice Low attenuation lymphadenopathy on computed tomography leading to diagnosis of Whipple disease. Medical Journal of Australia, 213(4), 161-162.e1.
2020 Gill, M., Blacketer, C., Chitti, F., Telfer, K., Papanicolas, L., Dann, L. M., . . . Costello, S. P. (2020). Physician and patient perceptions of fecal microbiota transplant for recurrent or refractory Clostridioides difficile in the first 6 years of a central stool bank. JGH Open, 4(5), 950-957.
Scopus10 WoS7 Europe PMC42020 Costello, S. P., Day, A., Yao, C. K., & Bryant, R. V. (2020). Faecal microbiota transplantation (FMT) with dietary therapy for acute severe ulcerative colitis.. BMJ Case Rep, 13(8), 3 pages.
Scopus17 WoS9 Europe PMC132020 Lett, B., Costello, S., & Roberts-Thomson, I. (2020). Analyzing the intestinal microbiome in inflammatory bowel disease: From RNA to multiomics. JGH Open, 4(5), 779-781.
Scopus1 Europe PMC12020 Noble, A., Durant, L., Hoyles, L., McCartney, A. L., Man, R., Segal, J., . . . Knight, S. C. (2020). Deficient Resident Memory T Cell and CD8 T Cell Response to Commensals in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 14(4), 525-537.
Scopus47 WoS36 Europe PMC362020 Rajagopalan, A., Sathananthan, D., An, Y. K., Van De Ven, L., Martin, S., Fon, J., . . . Bryant, R. V. (2020). Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. JGH Open, 4(2), 267-272.
Scopus36 WoS20 Europe PMC202020 Sathananthan, D., Rajagopalan, A., Van De Ven, L., Martin, S., Fon, J., Costello, S., & Bryant, R. V. (2020). Point-of-care gastrointestinal ultrasound in inflammatory bowel disease: An accurate alternative for disease monitoring. JGH Open, 4(2), 273-279.
Scopus14 WoS10 Europe PMC82020 Costello, S. P., & Bryant, R. V. (2020). Editorial: faecal microbiota transplantation—the silver bullet for severe and fulminant Clostridioides difficile infection?. Alimentary Pharmacology and Therapeutics, 51(1), 180-181.
2020 Haifer, C., Kelly, C. R., Paramsothy, S., Andresen, D., Papanicolas, L. E., McKew, G. L., . . . Leong, R. W. (2020). Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice.. Gut, 69(5), 801-810.
Scopus55 WoS46 Europe PMC362020 Ianiro, G., Mullish, B., Kelly, C., Sokol, H., Kassam, Z., Ng, S., . . . Cammarota, G. (2020). Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology and Hepatology, 5(5), 430-432.
Scopus110 WoS88 Europe PMC822020 Soo, W. T., Bryant, R. V., & Costello, S. P. (2020). Faecal microbiota transplantation: Indications, evidence and safety. Australian Prescriber, 43(2), 36-38.
Scopus2 WoS12020 Goodsall, T. M., Costello, S. P., & Bryant, R. V. (2020). Coronavirus disease 2019 (COVID-19) and implications for thiopurine use.. Med J Aust, 212(10), 490-490.e1.
Scopus5 WoS4 Europe PMC52020 Goodsall, T. M., Costello, S. P., & Bryant, R. V. (2020). ABC of topical therapy in inflammatory bowel disease. JGH Open, 4(4), 556-557.
Scopus2 WoS2 Europe PMC22019 Bryant, R., Schultz, C., Ooi, S., Goess, C., Costello, S., Vincent, A., . . . Andrews, J. (2019). Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life. Inflammatory bowel diseases, 25(3), 592-600.
Scopus48 WoS38 Europe PMC312019 Bryant, R. V., Schultz, C. G., Ooi, S., Goess, C., Costello, S. P., Vincent, A. D., . . . Andrews, J. M. (2019). Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life. Inflammatory bowel diseases, 25(6), e62-e63.
2019 Costello, S. P., Hughes, P. A., Waters, O., Bryant, R. V., Vincent, A. D., Blatchford, P., . . . Andrews, J. M. (2019). Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA - Journal of the American Medical Association, 321(2), 156-164.
Scopus608 WoS440 Europe PMC3552019 Costello, S., & Bryant, R. (2019). Faecal microbiota transplantation in Australia: bogged down in regulatory uncertainty. Internal Medicine Journal, 49(2), 148-151.
Scopus11 WoS7 Europe PMC52019 Papanicolas, L. E., Choo, J. M., Wang, Y., Leong, L. E. X., Costello, S. P., Gordon, D. L., . . . Rogers, G. B. (2019). Bacterial viability in faecal transplants: Which bacteria survive?. EBioMedicine, 41, 509-516.
Scopus97 WoS68 Europe PMC662019 Wardill, H., Secombe, K., Bryant, R., Hazenberg, M. D., & Costello, S. (2019). Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients. EBioMedicine, 44, 730-740.
Scopus52 WoS36 Europe PMC322019 Selvanderan, S. P., Goldblatt, F., Nguyen, N. Q., & Costello, S. P. (2019). Faecal microbiota transplantation for Clostridium difficile infection resulting in a decrease in psoriatic arthritis disease activity. Clinical and experimental rheumatology, 37(3), 514-515.
Scopus20 WoS15 Europe PMC132019 Bryant, R. V., & Costello, S. P. (2019). Editorial: assessing histological disease activity in Crohn’s disease—a call for standardisation of mucosal biopsy location. Alimentary Pharmacology and Therapeutics, 50(1), 103-104.
Scopus2 WoS2 Europe PMC12019 Costello, S. P., Conlon, M. A., & Andrews, J. M. (2019). Fecal microbiota transplantation for ulcerative colitis-Reply. JAMA - Journal of the American Medical Association, 321(22), 2240-2241.
Scopus5 WoS5 Europe PMC42019 Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., . . . Gasbarrini, A. (2019). International consensus conference on stool banking for faecal microbiota transplantation in clinical practice.. Gut, 68(12), 2111-2121.
Scopus317 WoS219 Europe PMC1772019 Kuijper, E. J., Allegretii, J., Hawkey, P., Sokol, H., Goldenberg, S., Ianiro, G., . . . Vehreschild, M. J. G. T. (2019). A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. The Lancet Infectious Diseases, 19(11), 1161-1162.
Scopus8 WoS7 Europe PMC42019 Roberts-Thomson, I. C., Bryant, R. V., & Costello, S. P. (2019). Uncovering the cause of ulcerative colitis.. JGH open : an open access journal of gastroenterology and hepatology, 3(4), 274-276.
Scopus15 WoS10 Europe PMC52018 Bryant, R., Schultz, C., Ooi, S., Goess, C., Costello, S., Vincent, A., . . . Andrews, J. (2018). Obesity in inflammatory bowel disease: gains in adiposity despite high prevalence of Myopenia and Osteopenia. Nutrients, 10(9), 1192-1-1192-17.
Scopus57 WoS44 Europe PMC292018 Bryant, R., Costello, S., Schoeman, S., Sathananthan, D., Knight, E., Lau, S. -Y., . . . Andrews, J. (2018). Limited uptake of ulcerative colitis 'treat to target' recommendations in real-world practice. Journal of gastroenterology and hepatology, 33(3), 599-607.
Scopus36 WoS26 Europe PMC192017 Costello, S. P., Soo, W., Bryant, R. V., Jairath, V., Hart, A. L., & Andrews, J. M. (2017). Editorial: faecal microbiota transplantation for ulcerative colitis—not quite there yet? Authors’ reply. Alimentary Pharmacology and Therapeutics, 46(6), 631-632.
2017 Costello, S., Soo, W., Bryant, R., Jairath, V., Hart, A., & Andrews, J. (2017). Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 46(3), 213-224.
Scopus215 WoS175 Europe PMC1392016 Costello, S., Tucker, E., La Brooy, J., Schoeman, M., & Andrews, J. (2016). Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clinical Infectious Diseases, 62(7), 908-914.
Scopus90 WoS78 Europe PMC562016 Hughes, P., Costello, S., Bryant, R., & Andrews, J. (2016). Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. American Journal of Physiology, 311(3), G501-G513.
Scopus21 WoS15 Europe PMC132016 Andrews, J. M., Costello, S. P., Agarwal, A. K., Bampton, P., Beswick, L., Connor, S., . . . Walsh, A. J. (2016). Conflict of interest: Real and perceived - a more mature consideration is needed. Internal Medicine Journal, 46(3), 377-379.
2015 Costello, S. P., Chung, A., Andrews, J. M., & Fraser, R. J. (2015). Fecal microbiota transplant for Clostridium difficile colitis-induced toxic megacolon. American Journal of Gastroenterology, 110(5), 775-777.
Scopus22 WoS22 Europe PMC132015 Costello, S., Ghaly, S., Beswick, L., Pudipeddi, A., Agarwal, A., Sechi, A., . . . Andrews, J. (2015). Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients. Internal Medicine Journal, 45(6), 659-666.
Scopus4 WoS3 Europe PMC32015 Costello, S., Conlon, M., Vuaran, M., Roberts-Thomson, I., & Andrews, J. (2015). Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: Clinical efficacy and bacterial viability data. Alimentary Pharmacology and Therapeutics, 42(8), 1011-1018.
Scopus110 WoS88 Europe PMC762015 Ghaly, S., Costello, S., Beswick, L., Pudipeddi, A., Agarwal, A., Sechi, A., . . . Andrews, J. (2015). Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response. Internal Medicine Journal, 45(2), 170-177.
Scopus7 WoS6 Europe PMC42015 Bryant, R. V., Costello, S. P., & Andrews, J. M. (2015). Editorial: Untangling symptoms from mucosal healing in UC - A note of caution for patient-reported outcomes. Alimentary Pharmacology and Therapeutics, 42(11-12), 1327-1328.
Scopus1 WoS1 Europe PMC12014 Andrews, J., & Costello, S. (2014). The emerging role of faecal microbiota transplantation. Medicine Today, 15(7), 62-64.
Scopus12011 Costello, S., & Singh, R. (2011). Endoscopic imaging in Barrett's oesophagus: Applications in routine clinical practice and future outlook. Clinical Endoscopy, 44(2), 87-92.
Scopus5 WoS4 Europe PMC32004 Teague, B., Morrison, C., Court, F., Chin, V., Costello, S., Kirkwood, I., & Maddern, G. (2004). Role of FDG-PET in surgical management of patients with colorectal liver metastases. Australian and New Zealand Journal of Surgery, 74(8), 646-652.
Scopus12 WoS8 Europe PMC6 -
Conference Papers
Year Citation 2023 Schubert, J., Tay, A., Lee, K. H. C., Leong, L., Rayner, C., Warner, W., . . . Bryant, R. (2023). Genomic analysis of Helicobacter pylori in Australia: Antimicrobial resistance, phylogenetic patterns, and virulence mutations. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 38 (pp. 221). Australia: WILEY.
DOI2022 Tucker, E., Haylock-Jacobs, S., Bryant, R. V., & Costello, S. (2022). Stool donor screening eligibility and retention with a Therapeutic Goods Order 105-compliant stool donor screening program for fecal microbiota transplantation. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 37 (pp. 208). WILEY. 2021 Schubert, J. P., Woodman, R. J., Mangoni, A. A., Rayner, C. K., Roberts-Thomson, I. C., Costello, S., & Bryant, R. V. (2021). Geospatial analysis of Helicobacter pylori infection in the Greater Adelaide region over 20 years: Should location influence choice of eradication therapy?. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 36 (pp. 137-138). Virtual online: WILEY. 2017 Noble, A., Durant, L., Hoyles, L., McCartney, A. L., Man, R., Costello, S. P., . . . Knight, S. C. (2017). Dysregulation of cellular vs humoral immunity to the intestinal microbiota in inflammatory bowel disease. In JOURNAL OF CROHNS & COLITIS Vol. 11 (pp. S123-S124). OXFORD UNIV PRESS. 2017 Costello, S. P., Van der Poorten, D., & Andrews, J. M. (2017). Fecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection: When regulatory affairs do not keep pace with evidence-based medicine. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 32 (pp. 156-157). WILEY. 2012 Agarwal, A., & Costello, S. P. (2012). Compassionate access (CA) use of anti-TNF therapy in inflammatory bowel disease (IBD) patients in Australia: an observational study. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 27 (pp. 96). WILEY-BLACKWELL. 2012 Costello, S. P., & Martin, J. (2012). Angioectasia in the Elderly is the Commonest Cause of Obscure Gastrointestinal Bleeding on Capsule Endoscopy. In GASTROINTESTINAL ENDOSCOPY Vol. 75 (pp. 260). San Diego, CA: MOSBY-ELSEVIER.
WoS2 -
Conference Items
Year Citation 2018 Rajagopalan, A., Sathananthan, D., Van De Ven, L., Martin, S., Fon, J., Costello, S. P., & Bryant, R. V. (2018). Gastrointestinal ultrasound in routine inflammatory bowel disease care: Acceptability, tolerability, and impact on illness-related knowledge. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY. 2018 Sathananthan, D., Rajagopalan, A., Van De Ven, L., Fon, J., Costello, S. P., & Bryant, R. V. (2018). Gastrointestinal ultrasound in routine inflammatory bowel disease care: Accuracy compared with colonoscopy and fecal calprotectin. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY. 2018 Hughes, P., Wardill, H., Dmochowska, N., Mavrangelos, C., Campaniello, M., Bowen, J., . . . Andrews, J. (2018). Proteolytic activation of IL-1 beta impairs epithelial barrier integrity in the ulcerative colitis lumen. Poster session presented at the meeting of Journal of Gastroenterology and Hepatology. Brisbane, Qld: Wiley. 2017 Costello, S. P., Waters, O., Bryant, R. V., Katsikeros, R., Makanyanga, J., Schoeman, M., . . . Andrews, J. M. (2017). SHORT DURATION, LOW INTENSITY, POOLED FECAL MICROBIOTA TRANSPLANTATION INDUCES REMISSION IN PATIENTS WITH MILD-MODERATELY ACTIVE ULCERATIVE COLITIS: A RANDOMISED CONTROLLED TRIAL. Poster session presented at the meeting of GASTROENTEROLOGY. Chicago, IL: W B SAUNDERS CO-ELSEVIER INC.
DOI WoS372017 Wardill, H. R., Dmochowska, N., Campaniello, M. A., Mavrangelos, C., Bowen, J. M., Andrews, J. M., . . . Hughes, P. A. (2017). Fecal supernatants from active ulcerative colitis patients impair colonic epithelial barrier integrity and activate pelvic mucosal extrinsic afferent nerves. Poster session presented at the meeting of FASEB Journal. Chicago, IL: Federation of American Societies for Experimental Biology.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Co-Supervisor Microbial manipulation as treatment for primary sclerosing cholangitis Doctor of Philosophy Doctorate Full Time Dr Damjana Bogatic 2024 Co-Supervisor Exploring the use of exclusive enteral nutrition in adult patients with Crohn's disease Doctor of Philosophy Doctorate Full Time Dr Matthew Chu 2023 Co-Supervisor Faecal Microbiota Transplant (FMT) as a safe and efficacious therapeutic alternative for refractory proctitis Doctor of Philosophy Doctorate Full Time Dr Sreecanth Raja
Connect With Me
External Profiles